A jab in the dark

The swine flu vaccine has landed, but the case numbers are up again. In the US, Barack Obama has declared a national emergency, and the vaccination queues are stretching round the block. Swine flu is a serious problem worldwide, but it is only a recent semantic twist that sees us name it as a pandemic. The World Health Organisation used to define a pandemic as a new virus that spread quickly, and for which there was no immunity, causing high mortality rates. In 2008, this was changed so that a new strain of a virus already in circulation could qualify as a pandemic. The minimum mortality rate that had to be reached before a pandemic could be declared was also scrapped.

This is important because it weighs heavily on the way governments respond to the problem. In general, I support vaccination. My concern about the swine flu vaccine isn’t that it could be harmful, but that it might not do a lot of good. Indeed, there’s plenty of evidence suggests that the best way to manage influenza is to keep infected people out of contact with non-infected people. This sounds simple in theory, but it is not easy in practice. Even when people feel decidedly flu-ish, they are remarkably reluctant to drop prior commitments; snuffling choristers will sing in a much-anticipated concert; friends will soldier into town for a Christmas lunch.

The remainder of this article can be read here. Please post comments below.

Health and science blog




This blog, part of the FT's health series, is a forum for readers interested in the science, policy, management, technology, business and delivery of healthcare.

This blog is no longer active but it remains open as an archive.
Follow on twitter

About our regular bloggers

Margaret McCartney is a Glasgow-based GP and FT Weekend columnist. She started writing for the Life and Arts section in 2005 and moved to the magazine in 2008. She also has her own blog: www.margaretmccartney.com/blog

Clive Cookson has been a science journalist for the whole of his working life. He joined the FT in 1987. Clive, the FT's science editor, picks out the research that everyone should know about. He also discusses key policy issues, from R&D funding to science education.

Andrew Jack is pharmaceuticals correspondent, covering the industry and public health issues. He has been a journalist with the FT for 19 years, based in London, Paris and Moscow

The Health blog: a guide

Comment: To comment, please register with FT.com, which you can do for free here. Please also read our comments policy here.
Contact: You can write to Ursula Milton, the blog's editor, using this email format: firstname.surname@ft.com
Time: UK time is shown on posts.
Follow: Links to the blog's Twitter and RSS feeds are at the top of the page. You can also read the Health blog on your mobile device, by going to www.ft.com/healthblog
FT blogs: See the full range of the FT's blogs here.